Literature DB >> 25819840

LC-MS/MS based assay and reference intervals in children and adolescents for oxysterols elevated in Niemann-Pick diseases.

Glynis Klinke1, Marianne Rohrbach2, Roberto Giugliani3, Patricie Burda2, Matthias R Baumgartner4, Christel Tran5, Matthias Gautschi6, Déborah Mathis7, Martin Hersberger8.   

Abstract

BACKGROUND: Niemann-Pick type C (NP-C) is a rare progressive neurodegenerative lipid storage disorder with heterogeneous clinical presentation and challenging diagnostic procedures. Recently oxysterols have been reported to be specific biomarkers for NP-C but knowledge on the intra-individual variation and on reference intervals in children and adolescents are lacking.
METHODS: We established a LC-MS/MS assay to measure Cholestane-3β, 5α, 6β-triol (C-triol) and 7-Ketocholesterol (7-KC) following Steglich esterification. To assess reference intervals and intra-individual variation we determined oxysterols in 148 children and adolescents from 0 to 18 years and repeat measurements in 19 of them.
RESULTS: The reported method is linear (r>0.99), sensitive (detection limit of 0.03 ng/mL [0.07 nM] for C-triol, and 0.54 ng/mL [1.35 nM] for 7-KC) and precise, with an intra-day imprecision of 4.8% and 4.1%, and an inter-day imprecision of 7.0% and 11.0% for C-triol (28 ng/ml, 67 nM) and 7-KC (32 ng/ml, 80 nM), respectively. Recoveries for 7-KC and C-triol range between 93% and 107%. The upper reference limit obtained for C-triol is 40.4 ng/mL (95% CI: 26.4-61.7 ng/mL, 96.0 nM, 95% CI: 62.8-146.7 nM) and 75.0 ng/mL for 7-KC (95% CI: 55.5-102.5 ng/mL, 187.2 nM, 95% CI: 138.53-255.8 nM), with no age or gender dependency. Both oxysterols have a broad intra-individual variation of 46%±23% for C-triol and 52%±29% for 7-KC. Nevertheless, all Niemann-Pick patients showed increased C-triol levels including Niemann-Pick type A and B patients.
CONCLUSIONS: The LC-MS/MS assay is a robust assay to quantify C-triol and 7-KC in plasma with well documented reference intervals in children and adolescents to screen for NP-C in the pediatric population. In addition our results suggest that especially the C-triol is a biomarker for all three Niemann-Pick diseases.
Copyright © 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS); Niemann–Pick; Oxysterols; Reference intervals; Steglich esterification

Mesh:

Substances:

Year:  2015        PMID: 25819840     DOI: 10.1016/j.clinbiochem.2015.03.007

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  22 in total

1.  N-acyl-O-phosphocholineserines: structures of a novel class of lipids that are biomarkers for Niemann-Pick C1 disease.

Authors:  Rohini Sidhu; Yawo Mondjinou; Mingxing Qian; Haowei Song; Arun Babu Kumar; Xinying Hong; Fong-Fu Hsu; Dennis J Dietzen; Nicole M Yanjanin; Forbes D Porter; Elizabeth Berry-Kravis; Charles H Vite; Michael H Gelb; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  J Lipid Res       Date:  2019-06-14       Impact factor: 5.922

2.  Diagnosis of niemann-pick C1 by measurement of bile acid biomarkers in archived newborn dried blood spots.

Authors:  Xuntian Jiang; Rohini Sidhu; Joseph J Orsini; Nicole Y Farhat; Forbes D Porter; Elizabeth Berry-Kravis; Jean E Schaffer; Daniel S Ory
Journal:  Mol Genet Metab       Date:  2018-08-24       Impact factor: 4.797

3.  Application of a glycinated bile acid biomarker for diagnosis and assessment of response to treatment in Niemann-pick disease type C1.

Authors:  Rohini Sidhu; Pamela Kell; Dennis J Dietzen; Nicole Y Farhat; An Ngoc Dang Do; Forbes D Porter; Elizabeth Berry-Kravis; Janine Reunert; Thorsten Marquardt; Roberto Giugliani; Charles M Lourenço; Raymond Y Wang; Nina Movsesyan; Ellen Plummer; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  Mol Genet Metab       Date:  2020-11-18       Impact factor: 4.797

4.  Advancing Diagnosis and Treatment of Niemann-Pick C disease through Biomarker Discovery.

Authors:  Xuntian Jiang; Daniel S Ory
Journal:  Explor Neuroprotective Ther       Date:  2021-12-30

Review 5.  Contribution of tandem mass spectrometry to the diagnosis of lysosomal storage disorders.

Authors:  Monique Piraud; Magali Pettazzoni; Pamela Lavoie; Séverine Ruet; Cécile Pagan; David Cheillan; Philippe Latour; Christine Vianey-Saban; Christiane Auray-Blais; Roseline Froissart
Journal:  J Inherit Metab Dis       Date:  2018-03-19       Impact factor: 4.982

Review 6.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.

Authors:  Apostolos Papandreou; Paul Gissen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

7.  Evaluation of plasma cholestane-3β,5α,6β-triol and 7-ketocholesterol in inherited disorders related to cholesterol metabolism.

Authors:  Sara Boenzi; Federica Deodato; Roberta Taurisano; Bianca Maria Goffredo; Cristiano Rizzo; Carlo Dionisi-Vici
Journal:  J Lipid Res       Date:  2016-01-05       Impact factor: 5.922

8.  Cholestane-3β,5α,6β-triol: high levels in Niemann-Pick type C, cerebrotendinous xanthomatosis, and lysosomal acid lipase deficiency.

Authors:  Sonia Pajares; Angela Arias; Judit García-Villoria; Judit Macías-Vidal; Emilio Ros; Javier de las Heras; Marisa Girós; Maria J Coll; Antonia Ribes
Journal:  J Lipid Res       Date:  2015-08-03       Impact factor: 5.922

Review 9.  Niemann-Pick type C disease: The atypical sphingolipidosis.

Authors:  Jason Newton; Sheldon Milstien; Sarah Spiegel
Journal:  Adv Biol Regul       Date:  2018-08-28

10.  Application of N-palmitoyl-O-phosphocholineserine for diagnosis and assessment of response to treatment in Niemann-Pick type C disease.

Authors:  Rohini Sidhu; Pamela Kell; Dennis J Dietzen; Nicole Y Farhat; An Ngoc Dang Do; Forbes D Porter; Elizabeth Berry-Kravis; Charles H Vite; Janine Reunert; Thorsten Marquardt; Roberto Giugliani; Charles M Lourenço; Olaf Bodamer; Raymond Y Wang; Ellen Plummer; Jean E Schaffer; Daniel S Ory; Xuntian Jiang
Journal:  Mol Genet Metab       Date:  2020-01-22       Impact factor: 4.204

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.